Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pieris Pharma Appoints Chief Development Officer

This article was originally published in Scrip

Executive Summary

Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its Anticalin technology platform, has named Dr. Louis Matis senior vice-president and chief development officer. Prior to joining Pieris, Matis was, since June 2011, executive director of strategic evaluation at Alexion Pharmaceuticals. He also worked at Alexion from 1993 to 2000, during which time he advanced to the position of chief scientific officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris (eculizumab).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel